Pat Sacco

Pat is highly experienced as a biotechnology and life sciences executive in technical and general operations, including manufacturing, supply chain, CMC, quality, process sciences, and engineering. Most recently, as an independent consultant, he has worked with a number of advanced therapy medicinal product (ATMP) biotech companies, CDMOs, and specialized program management clients. Previously, he was the Senior Vice President of Technical Operations at both Translate Bio and Shire (now Takeda), and prior to that held roles of increasing responsibility at Wyeth Biopharma (formerly Genetics Institute) and Genzyme. He has contributed to the development, manufacturing, and commercialization of enzyme replacement therapies, REPLAGAL, ELAPRASE, and VPRIV.

Pat holds a Bachelor of Science degree in Chemical Engineering and Biotechnology from Worcester Polytechnic Institute (WPI). He also serves as a board member of NewAge Industries Inc., QbDVision Inc., and as an advisory board member of Vernal Biosciences Inc.